semaglutide asthma GLP1 weight loss injections may reduce symptoms RACGP - Evidence 'growing' for

Retatrutide builds on everything tirzepatide does and adds the glucagon receptor component

Thus, the vagal sensory neurons that express the receptor and respond to the systemic administration of GLP-1R agonists do not synaptically target the hindbrain GLP-1 neurons

F., & Mendez, M

Setting realistic expectations prevents both disappointment and premature discontinuation

Novo CagriSema (cagrilintide + semaglutide) In REDEFINE-4 (84 weeks), CagriSema 2.4/2.4 mg delivered: 23.0% weight loss (efficacy estimand) 20.2% (treatment-regimen estimand) Missed non-inferiority vs tirzepatide Takeaway: Clinically strong, but not a category reset

Cardiovascular Markers GLP-1 medications have demonstrated cardiovascular benefits in clinical trials